Polycythemia vera (PV) Program in Pharmaceutical Benefits Scheme (PBS) 012-25080641

PV restriction and item codes

Do not share this attachment externally. See Freedom of Information - Information Publication Scheme.
$\\INTERNAL.DEPT.LOCAL\Shared\NAT\SERDELEXCEL\WORKPRODIMP\Operation Blueprint Migration\RDT Release Icons\32w\icon-hidden-attachment.png$ PBS PV restriction and item codes

Contact details

PBS Complex Drugs Programs

Form

Polycythemia vera - ruxolitinib - initial authority application (PB388)

Services Australia website

Polycythemia vera

External website

PBS schedule for Polycythemia vera

FAQs from Service Officers

Table 1: see Table 2 in Processing Complex Authority Required Listings for FAQs about all Complex programs.

Item	Description
1	Is there an age restriction for patients applying for PBS-subsidised ruxolitinib to treat PV? Yes. Patients must be aged 18 years or older.
2	Can quantity and repeats of PBS-subsidised ruxolitinib be increased for the treatment of PV? No increase in the maximum quantity of 56 tablets and 5 repeats can be authorised.
3	Are questions and answers (Q&A) attached to relevant restrictions of PV available in the National Drug Reference Database (NDRD)? No. PV authority applications are assessed by Dynamic Q&A in the Online PBS Authorities (OPA) system. For troubleshooting see Resources > Dynamic Question and Answers (DQA) resources in Dosage calculators and charts for Pharmaceutical Benefits Scheme (PBS).
4	Can a patient be approved for more than one balance of initial? Yes. Provided the prescriber confirms that the patient has not had more than 24 weeks under the balance of initial restriction and 48 weeks of treatment in total, more than one request can be approved (example, for a change of dose).
5	Is ruxolitinib PBS listed for any other indications? Yes. Ruxolitinib is available on the PBS general authority line for the treatment of myelofibrosis.